Document is current
Any future updates will be listed below
-
Authors
Feist, Eugen https://orcid.org/0000-0002-9872-5282
Luggen, Michael E.
Nasonov, Evgeny L.
Yakushin, Sergey S.
Bukhanova, Daria V.
Egorova, Alina N.
Grishin, Sergey A.
Samsonov, Mikhail Y.
Smolen, Josef S.
-
Funding
Funding for this research was provided by:
Otto-von-Guericke-Universität Magdeburg
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 26 October 2025
First Online: 14 November 2025
Declarations
:
: Not applicable. This is a post hoc analysis. All the relevant information was provided in the publication that describes the main study results (Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022;387(8):715–726. doi: ).
: EF reports grants or research support: Eli Lilly, Novartis, Pfizer; serving as a consultant for AbbVie, Eli Lilly, Galapagos, Medac, Novartis, Sanofi, Sobi, R-Pharm; ML reports grants/research support: AbbVie, Biogen, GSK, Lilly, R-Pharm, Sun Pharma, UCB. EN serves as a consultant for R-Pharm. SY reports grants or research support: Eli Lilly, Abbvie, R-Pharm, MSD; serving as a consultant for Novartis, Pfizer, Servier, Bayer, Sanofi, Gedeon Richter, AstraZeneca, КRKA, Egis, Berlin-Chemie, Viatris, Nizhpharm, Akrikhin; DB is an employee of RPharm; AE is an employee of R-Pharm; SG is an employee of R-Pharm; MS is an employee of R-Pharm; JS reports grants/research support: AbbVie, BMS, Celgene, Chugai, Eli Lilly, Gilead, Janssen, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB; serving as a consultant for AbbVie, BMS, Celgene, Chugai, Eli Lilly, Gilead, Janssen, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB.
